Annals of Surgical Oncology

, Volume 16, Issue 6, pp 1526–1536 | Cite as

Surgical Management of Melanoma-In-Situ Using a Staged Marginal and Central Excision Technique

  • Mecker G. Möller
  • Effie Pappas-Politis
  • Jonathan S. Zager
  • Luis A. Santiago
  • Daohai Yu
  • Amy Prakash
  • Adam Kinal
  • Graham S. Clark
  • Weiwei Zhu
  • Christopher A. Puleo
  • L. Frank Glass
  • Jane L. Messina
  • Vernon K. Sondak
  • C. Wayne  Cruse


Melanoma-in-situ (MIS) represents 45% of all melanomas. The margins of MIS are often poorly defined with extensive subclinical disease. Standard fusiform excision with 5-mm margins results in positive margins in up to a third of cases. To decrease the incidence of involved margins, we use a staged excision approach for MIS. First, patients undergo excision under local anesthesia of a 2- to 3-mm “contoured” rim of tissue optimally 5 mm beyond the visible extent of the lesion. Formalin-fixed paraffin-embedded en face sections from this excision are then evaluated, if necessary with the aid of immunohistochemical stains. Any positive margins are further excised. When all margins are negative, the central area is then excised and reconstructed. A total of 61 patients with MIS or lentigo maligna melanoma underwent staged contoured excisions from 2004 to 2007 at Moffitt Cancer Center. We analyzed data only from patients with MIS of the head and neck. Patients with known invasive melanoma or non–head and neck primary disease were excluded. Demographics, tumor characteristics, margin status, number of stages, and type of reconstruction and recurrences were evaluated. Forty-nine patients with MIS of the head and neck, 28 (57%) male and 21 (43%) female, 42 to 88-years-old (median 72; mean 70), underwent staged contoured margin excision before definitive central tumor excision and reconstruction. The final surgical defect size ranged from 2 to 130 cm2 (median 16 cm2). Twelve patients (24%) required reexcision of at least one margin; the median number of reexcisions was 1 (range 1–2). There seemed to be a positive association between lesion size and margin status (as well as number of excisions needed to clear the margin). Unsuspected invasive melanoma was found in the central specimen in six patients (12%). Even small tumors could have unsuspected invasive melanoma: invasive cancer was seen in 4 (21%) of 19 tumors ≤2 cm in greatest dimension and 2 (7%) of 30 > 2 cm, respectively. Surgical defects were reconstructed with flaps in 18 (37%), full-thickness grafts in 20 (41%), and split-thickness grafts in 10 patients (20%). Median time from first margin excision to completion/final reconstruction was 7 days (range 7–63 days). No local recurrences have been reported at a median follow-up of 14 months (range 1–36 months). This technique allows for careful margin analysis and subsequent central tumor excision with simultaneous reconstruction. This approach minimizes the need for a second major operation, which would have been necessary in 24% of our patients if treated by a one-stage excisional approach. It is noteworthy that 12% of MIS patients had invasive melanoma in the final excision specimen. This reinforces the importance of adequate full-thickness biopsies of suspicious pigmented lesions before any type of surgical management. With short follow-up, local control has been achieved by this technique in 100% of cases.


  1. 1.
    Davis T, Zembowicz A. Histological evolution of lentiginous melanoma: a report of five new cases. J Cutan Pathol. 2007;34:296–300.PubMedCrossRefGoogle Scholar
  2. 2.
    Tannous ZS, Lerner LH, Duncan LM, et al. Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type. Hum Pathol. 2000;31:705–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1995;33:923–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Wayte DM, Helwig EB. Melanotic freckle of Hutchinson. Cancer. 1968;21:893–911.PubMedCrossRefGoogle Scholar
  5. 5.
    Bub JL, Berg D, Slee A, et al. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol. 2004;140:552–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Kelly JW. Following lentigo maligna may not prevent the development of life-threatening melanoma. Arch Dermatol. 1992;128:657–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Breuninger H, Schlagenhauff B, Stroebel W, et al. Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation. Am J Surg Pathol. 1999;23:1493–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1997;36(6 Pt 1):913.PubMedGoogle Scholar
  9. 9.
    Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol. 1987;116:303–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Jones WO, Harman CR, Ng AK, et al. Incidence of malignant melanoma in Auckland, New Zealand: highest rates in the world. World J Surg. 1999;23:732–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Newell GR, Sider JG, Bergfelt L, et al. Incidence of cutaneous melanoma in the United States by histology with special reference to the face. Cancer Res. 1988;48:5036–41.PubMedGoogle Scholar
  12. 12.
    Swetter SM, Boldrick JC, Jung SY, et al. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990–2000. J Invest Dermatol. 2005;125:685–91.PubMedCrossRefGoogle Scholar
  13. 13.
    NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA. 1992 ;268:1314–9.CrossRefGoogle Scholar
  14. 14.
    National Comprehensive Cancer Network clinical practice guidelines in oncology: melanoma. v.2.2007. Available at: Accessed September 1, 2007.
  15. 15.
    Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218:262–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126:438–41.Google Scholar
  17. 17.
    Grande DJ, Koranda FC, Whitaker DC. Surgery of extensive, subclinical lentigo maligna. J Dermatol Surg Oncol. 1982;8:493–6.PubMedGoogle Scholar
  18. 18.
    Albertini JG, Elston DM, Libow LF, et al. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol Surg. 2002;28:656–65.PubMedCrossRefGoogle Scholar
  19. 19.
    Osborne JE, Hutchinson PE. A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br J Plast Surg. 2002;55:611–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg. 2004;30:403–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Huilgol SC, Selva D, Chen C, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol. 2004;140:1087–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Zalla MJ, Lim KK, Dicaudo DJ, et al. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg. 2000;26:771–84.PubMedCrossRefGoogle Scholar
  23. 23.
    Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol. 2002;47:743–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Pitman GH, Kopf AW, Bart RS, et al. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol. 1979;5:727–37.PubMedGoogle Scholar
  25. 25.
    Coleman WP 3rd, Davis RS, Reed RJ, et al. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol. 1980;6:476–9.PubMedGoogle Scholar
  26. 26.
    Anderson KW, Baker SR, Lowe L, et al. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg. 2001;3:202–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J Surg Oncol. 2005;91:120–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Somach SC, Taira JW, Pitha JV, et al. Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens. Arch Dermatol. 1996;132:1297–302.PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol Surg. 1998;24:673–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg. 2007;33:395–402.PubMedCrossRefGoogle Scholar
  31. 31.
    Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J Am Acad Dermatol. 2002;46:78–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Davis DA, Kurtz KA, Robinson RA. Ultrarapid staining for cutaneous melanoma: study and protocol. Dermatol Surg 2005;31(7 Pt 1):753–6.PubMedGoogle Scholar
  33. 33.
    Hendi A, Brodland DG, Zitelli JA. Melanocytes in long-standing sun-exposed skin: quantitative analysis using the MART-1 immunostain. Arch Dermatol. 2006;142:871–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Megahed M, Schon M, Selimovic D, et al. Reliability of diagnosis of melanoma in situ. Lancet. 2002;359(9321):1921–2.PubMedCrossRefGoogle Scholar
  35. 35.
    Johnson TM, Headington JT, Baker SR, et al. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure. J Am Acad Dermatol. 1997;37(5 Pt 1):758–64.PubMedCrossRefGoogle Scholar
  36. 36.
    McKenna JK, Florell SR, Goldman GD, et al. Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg. 2006;32:493–504.PubMedCrossRefGoogle Scholar
  37. 37.
    Hill DC, Gramp AA. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australas J Dermatol. 1999;40:25–30.PubMedCrossRefGoogle Scholar
  38. 38.
    Jejurikar SS, Borschel GH, Johnson TM, et al. Immediate, optimal reconstruction of facial lentigo maligna and melanoma following total peripheral margin control. Plast Reconstr Surg. 2007;120:1249–55.PubMedCrossRefGoogle Scholar
  39. 39.
    Mahoney EJ, Dolan RW, Choi EE, et al. Surgical reconstruction of lentigo maligna defects. Arch Facial Plast Surg. 2005;7:342–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol. 2006;94:287–92.PubMedCrossRefGoogle Scholar
  41. 41.
    Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol 1997;37(2 Pt 1):236–45.PubMedCrossRefGoogle Scholar
  42. 42.
    Zalaudek I, Horn M, Richtig E, et al. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol. 2003;148:703–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Stevenson O, Ahmed I. Lentigo maligna: prognosis and treatment options. Am J Clin Dermatol. 2005;6:151–64.PubMedCrossRefGoogle Scholar
  44. 44.
    Malhotra R, Chen C, Huilgol SC, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology. 2003;110:2011–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Walling HW, Scupham RK, Bean AK, et al. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 2007;57:659–64.PubMedCrossRefGoogle Scholar
  46. 46.
    Bhardwaj SS, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol Surg. 2006;32:690–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Bricca GM, Brodland DG, Ren D, et al. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:92–100.PubMedCrossRefGoogle Scholar
  48. 48.
    Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg. 2003;7:25–30.PubMedCrossRefGoogle Scholar
  49. 49.
    Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37(3 Pt 1):422–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Dhawan SS, Wolf DJ, Rabinovitz HS, et al. Lentigo maligna. The use of rush permanent sections in therapy. Arch Dermatol. 1990;126:928–30.PubMedCrossRefGoogle Scholar
  51. 51.
    Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol. 1994;31:79–85.PubMedCrossRefGoogle Scholar
  52. 52.
    Cohen LM, McCall MW, Hodge SJ, et al. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs’ micrographic surgery aided by rush permanent sections. Cancer. 1994;73:2964–70.PubMedCrossRefGoogle Scholar
  53. 53.
    Zitelli JA. Surgical margins for lentigo maligna, 2004. Arch Dermatol. 2004;140:607–8.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Mecker G. Möller
    • 1
  • Effie Pappas-Politis
    • 2
  • Jonathan S. Zager
    • 1
    • 3
  • Luis A. Santiago
    • 2
  • Daohai Yu
    • 3
    • 4
    • 5
  • Amy Prakash
    • 6
  • Adam Kinal
    • 7
  • Graham S. Clark
    • 7
  • Weiwei Zhu
    • 4
  • Christopher A. Puleo
    • 1
  • L. Frank Glass
    • 1
    • 7
  • Jane L. Messina
    • 1
    • 6
    • 7
  • Vernon K. Sondak
    • 1
    • 2
    • 3
  • C. Wayne  Cruse
    • 1
    • 2
  1. 1.Department of Cutaneous OncologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  2. 2.Department of SurgeryUniversity of South Florida College of MedicineTampaUSA
  3. 3.Department of Oncologic SciencesUniversity of South Florida College of MedicineTampaUSA
  4. 4.Department of BiostatisticsH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  5. 5.Department of Epidemiology and BiostatiscticsUniversity of South Florida College of MedicineTampaUSA
  6. 6.Department of Pathology and Cell BiologyUniversity of South Florida College of MedicineTampaUSA
  7. 7.Department of Dermatology and Cutaneous SurgeryUniversity of South Florida College of MedicineTampaUSA

Personalised recommendations